

SEER Site-Specific Coding Guidelines
THYROID GLAND
C739

Coding Hormone Therapy

Hormones as Replacement Therapy – Do Not Code as Treatment

The thyroid gland produces hormones that influence essentially every organ, tissue and cell in the body. When the thyroid is partially or totally removed, it is no longer able to secrete these essential hormones and the patient is placed on hormone replacement therapy. Do not code replacement therapy as treatment.

Hormone Treatment for Follicular Thyroid Cancer – Code in the Hormone Field

The growth of follicular cell cancer depends on thyroid stimulating hormone. Suppression of these hormones is thought to deprive the cells of a growth-promoting influence. Patients with follicular cell-derived cancers have been treated with supraphysiologic doses of thyroid hormone to suppress serum thyroid-stimulating hormones. This treatment has been an industry standard for more than forty years. Record the delivery of these hormones in the Hormone treatment field.

Generic Thyroid Drug Names

Levothyroxine /L-thyroxine
Liothyronine
Liotrix
Methimazole
Natural Thyroid
Propylthiouracil / PTU
Thyrotropin alfa

Thyroid Drugs Brand Names

Armour Thyroid
Cytomel
Levothroid
Levoxyl
Naturethroid
Synthroid
Tapazole
Thyrogen
Thyrolar
Unithroid
Westhroid

Page intentionally blank

Collaborative Staging Codes

Thyroid Gland

C73.9

C73.9 Thyroid gland

CS Tumor Size	CS Site-Specific Factor 1 - Solitary vs Multifocal	The following tables are available at the collaborative staging website: Histology Exclusion Table AJCC Stage-Thyroid: Papillary and Follicular - Age less than 45 Extension Size Table Histologies-Thyroid AJCC Stage-Thyroid: Papillary and Follicular - Age 45 and older AJCC Stage-Thyroid: Medullary AJCC Stage-Thyroid: Anaplastic
CS Extension	CS Site-Specific Factor 2	
CS TS/Ext-Eval	CS Site-Specific Factor 3	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Reg Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam		
CS Mets at DX		
CS Mets Eval		

Thyroid Gland

CS Tumor Size

SEE STANDARD TABLE

Thyroid Gland

CS Extension

Note: AJCC considers all anaplastic carcinomas to be T4. Collaborative Staging has implemented this as follows: If histology is equal to 8020 or 8021 and if CS Extension is equal to 00, 10, 20, 30, 40, 45, or 48, then T category is equal to T4a. For these histologies, if CS Extension is equal to 50, 52, 60, 62, 70, 72, or 80, then T category is equal to T4b. If CS Extension is equal to 95 or 99, the T category is T4NOS. For all other histologies, follow the rules as shown in the tables.

Code	Description	TNM	SS77	SS2000
00	In situ; non-invasive	Tis	IS	IS
10	Single invasive tumor confined to thyroid	*	L	L
20	Multiple foci confined to thyroid	*	L	L
30	Localized, NOS	*	L	L
40	Into thyroid capsule, but not beyond	*	L	L
45	Minimal extrathyroid extension including: Strap muscle(s): Omohyoid Sternohyoid Sternothyroid	T3	RE	RE
48	Pericapsular soft/connective tissue	T3	RE	RE
50	Parathyroid Nerves: Recurrent laryngeal Vagus	T4a	RE	RE

52	Cricoid cartilages Esophagus Larynx Sternocleidomastoid muscle	T4a	RE	RE
60	Thyroid cartilage Tumor is described as "FIXED to adjacent tissues"	T4b	RE	RE
62	Blood vessel(s) (major): Carotid artery Jugular vein Thyroid artery or vein	T4b	RE	RE
70	Bone Skeletal muscle, other than strap or sternocleidomastoid muscle	T4b	D	D
72	Trachea	T4a	D	D
80	Further contiguous extension Mediastinal tissues Prevertebral fascia	T4b	D	D
95	No evidence of primary tumor	T0	U	U
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	TX	U	U

* For Extension codes 10, 20, 30, and 40 ONLY, the T category is assigned based on value of CS Tumor Size from Extension Size Table.

Thyroid Gland
CS TS/Ext-Eval
SEE STANDARD TABLE

Thyroid Gland
CS Lymph Nodes

Note: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX.

Code	Description	TNM	SS77	SS2000
00	None; no regional lymph node involvement	N0	NONE	NONE
10	Ipsilateral regional lymph nodes: Anterior deep cervical (laterotracheal) (recurrent laryngeal): Paralaryngeal Paratracheal Prealaryngeal Pretracheal Cervical, NOS Internal jugular, NOS: Deep cervical, NOS: Lower, NOS Jugulo-omohyoid (supraomohyoid) Middle Retropharyngeal Spinal accessory (posterior cervical)	N1a	RN	RN

11	Regional lymph nodes: Delphian node Mediastinal, NOS Posterior mediastinal (tracheoesophageal) Upper anterior mediastinal Supraclavicular (transverse cervical)	N1a	D	RN
20	Regional lymph nodes as listed in code 10 Bilateral, contralateral, or midline cervical nodes	N1b	RN	RN
21	Regional lymph nodes as listed in code 11 Bilateral, contralateral, or midline cervical nodes	N1b	D	RN
30	Tracheoesophageal (posterior mediastinal)	N1b	RN	RN
31	Mediastinal, NOS Upper anterior mediastinal	N1b	D	RN
50	Regional lymph node(s), NOS	N1NOS	RN	RN
80	Lymph nodes, NOS	N1NOS	RN	RN
99	Unknown; not stated Regional lymph node(s) cannot be assessed Not documented in patient record	NX	U	U

Thyroid Gland

CS Reg Nodes Eval

SEE STANDARD TABLE

Thyroid Gland

Reg LN Pos

SEE STANDARD TABLE

Thyroid Gland

Reg LN Exam

SEE STANDARD TABLE

Thyroid Gland

CS Mets at DX

Code	Description	TNM	SS77	SS2000
00	No; none	M0	NONE	NONE
10	Distant lymph node(s) Mandibular, NOS	M1	D	D
11	Distant lymph node(s) Submandibular (submaxillary) Submental	M1	D	D
12	Distant lymph node(s) other than in code 10 or 11 Distant lymph node(s), NOS	M1	D	D

40	Distant metastases except distant lymph node(s) (code 10) Distant metastasis, NOS Carcinomatosis	M1	D	D
50	(40) + or any of [(10) to (12)] Distant lymph node(s) plus other distant metastasis)	M1	D	D
99	Unknown if distant metastasis Distant metastasis cannot be assessed Not documented in patient record	MX	U	U

Thyroid Gland

CS Mets Eval

SEE STANDARD TABLE

Thyroid Gland

CS Site-Specific Factor 1 Solitary vs Multifocal

Code	Description
000	None
001	Solitary tumor
002	Multifocal tumor [AJCC descriptor (m)]
999	Insufficient information Not documented in patient record

Thyroid Gland

CS Site-Specific Factor 2

Code	Description
888	Not applicable for this site

Thyroid Gland

CS Site-Specific Factor 3

Code	Description
888	Not applicable for this site

Thyroid Gland

CS Site-Specific Factor 4

Code	Description
888	Not applicable for this site

Thyroid Gland

CS Site-Specific Factor 5

Code	Description
888	Not applicable for this site

Thyroid Gland
CS Site-Specific Factor 6

Code	Description
888	Not applicable for this site

Page intentionally blank

Collaborative Staging Codes

Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands

C37.9, C74.0-C74.1, C74.9, C75.0-C75.5, C75.8-C75.9

Note: Laterality must be coded for sites C74.0, C74.1, C74.9, and C75.4.

C37.9 Thymus

C74.0 Cortex of adrenal gland

C74.1 Medulla of adrenal gland

C74.9 Adrenal gland, NOS

C75.0 Parathyroid gland

C75.1 Pituitary gland

C75.2 Craniopharyngeal duct

C75.3 Pineal gland

C75.4 Carotid body

C75.5 Aortic body and other paraganglia

C75.8 Overlapping lesion of endocrine glands and related structures

C75.9 Endocrine gland, NOS

Note: AJCC does not define TNM staging for this site.

CS Tumor Size	CS Site-Specific Factor 1 - WHO	The following tables are available at the collaborative staging website: Histologies for Which AJCC Staging Is Not Generated AJCC Stage
CS Extension	Grade Classification	
CS TS/Ext-Eval	CS Site-Specific Factor 2	
CS Lymph Nodes	CS Site-Specific Factor 3	
CS Reg Nodes Eval	CS Site-Specific Factor 4	
Reg LN Pos	CS Site-Specific Factor 5	
Reg LN Exam	CS Site-Specific Factor 6	
CS Mets at DX		
CS Mets Eval		

Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands

CS Tumor Size

SEE STANDARD TABLE

Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands

CS Extension

Code	Description	TNM	SS77	SS2000
00	In situ; non-invasive; intraepithelial	NA	IS	IS
05	For C75.1 pituitary gland, C75.2 craniopharyngeal duct and C75.3 pineal gland ONLY: Benign or borderline tumors	NA	NA	NA
10	Invasive carcinoma confined to gland of origin	NA	L	L
30	Localized, NOS	NA	L	L
40	Adjacent connective tissue (see definition in General Instructions)	NA	RE	RE

60	Adjacent organs/structures Thymus and aortic body: Organs/structures in mediastinum Adrenal (suprarenal): Kidney Retroperitoneal structures Parathyroid Thyroid Thyroid cartilage Pituitary and craniopharyngeal duct: Cavernous sinus Infundibulum Pons Sphenoid body and sinuses Pineal: Infratentorial and central brain Carotid body: Upper neck	NA	RE	RE
80	Further contiguous extension	NA	D	D
95	No evidence of primary tumor	NA	U	U
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	NA	U	U

Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands

CS TS/Ext-Eval

Code	Description	Staging Basis
9	Not applicable for this site	NA

Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands

CS Lymph Nodes

Note 1: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX.

Note 2: Use code 99, not applicable, for the following sites: Pituitary gland (C75.1), Craniopharyngeal duct (C75.2), and Pineal gland (C75.3)

Code	Description	TNM	SS77	SS2000
00	None; no regional lymph node involvement	NA	NONE	NONE
10	Regional lymph nodes Cervical for carotid body and parathyroid only Mediastinal for aortic body and thymus only Retroperitoneal for adrenal (suprarenal) gland only	NA	RN	RN
80	Lymph nodes, NOS	NA	RN	RN
99	Unknown; not stated Regional lymph node(s) cannot be assessed Not documented in patient record For Pituitary gland (C75.1), Craniopharyngeal duct (C75.2), and Pineal gland (C75.3): Not applicable	NA	U	U

**Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands
CS Reg Nodes Eval**

Code	Description	Staging Basis
9	Not applicable for this site	NA

**Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands
Reg LN Pos
SEE STANDARD TABLE**

**Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands
Reg LN Exam
SEE STANDARD TABLE**

**Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands
CS Mets at DX**

Code	Description	TNM	SS77	SS2000
00	No; none	NA	NONE	NONE
10	Distant lymph node(s), NOS	NA	D	D
40	Distant metastases except distant lymph node(s) (code 10) Distant metastasis, NOS Carcinomatosis	NA	D	D
50	(10) + (40) Distant lymph node(s) plus other distant metastases	NA	D	D
99	Unknown if distant metastasis Cannot be assessed Not documented in patient record	NA	U	U

**Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands
CS Mets Eval**

Code	Description	Staging Basis
9	Not applicable for this site	NA

**Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands
CS Site-Specific Factor 1 WHO Grade Classification**

Note 1: WHO grade applies only to C75.1 pituitary gland, C75.2 craniopharyngeal duct, C75.3 pineal gland. For all other sites in this schema, enter code 999.

Note 2: Code the WHO Grade Classification as documented in the medical record.

Code	Description
010	Grade I
020	Grade II
030	Grade III

040	Grade IV
999	Clinically diagnosed/grade unknown Not documented in medical record Grade unknown, NOS

Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands

CS Site-Specific Factor 2

Code	Description
888	Not applicable for this site

Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands

CS Site-Specific Factor 3

Code	Description
888	Not applicable for this site

Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands

CS Site-Specific Factor 4

Code	Description
888	Not applicable for this site

Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands

CS Site-Specific Factor 5

Code	Description
888	Not applicable for this site

Thymus, Adrenal (Suprarenal) Gland, and Other Endocrine Glands

CS Site-Specific Factor 6

Code	Description
888	Not applicable for this site

Collaborative Staging Codes
Kaposi Sarcoma of All Sites
(M-9140)

Note: This scheme cannot be compared to either the Historic Stage or the 1977 Summary Stage schemes.

CS Tumor Size	CS Site-Specific Factor 1 - Associated with HIV/AIDS	The following tables are available at the collaborative staging website: Histologies for Which AJCC Staging Is Not Generated AJCC Stage
CS Extension	CS Site-Specific Factor 2	
CS TS/Ext-Eval	CS Site-Specific Factor 3	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Reg Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam		
CS Mets at DX		
CS Mets Eval		

Kaposi Sarcoma of All Sites
CS Tumor Size

Code	Description
888	Not applicable

Kaposi Sarcoma of All Sites
CS Extension

Code	Description	TNM	SS77	SS2000
11	Single lesion: Skin	NA	U	L
12	Single lesion: Mucosa (e.g., oral cavity, anus, rectum, vagina, vulva)	NA	U	L
13	Single lesion: Viscera (e.g., pulmonary, gastrointestinal tract, spleen, other)	NA	U	L
21	Multiple lesions: Skin	NA	U	L
22	Multiple lesions: Mucosa (e.g., oral cavity, anus, rectum, vagina, vulva)	NA	U	L
23	Multiple lesions: Viscera (e.g., pulmonary, gastrointestinal tract, spleen, other)	NA	U	L
24	(21) + (22)	NA	U	RE
25	(21) + (23)	NA	U	RE
26	(22) + (23)	NA	U	RE
27	(21) + (22) + (23)	NA	U	D
29	Multiple lesions, NOS	NA	U	U
95	No evidence of primary tumor	NA	U	U

99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	NA	U	U
----	---	----	---	---

Kaposi Sarcoma of All Sites

CS TS/Ext-Eval

Code	Description	Staging Basis
9	Not applicable for this site	NA

Kaposi Sarcoma of All Sites

CS Lymph Nodes

Note: For this site, code ALL lymph node involvement in this field.

Code	Description	TNM	SS77	SS2000
00	No lymph node involvement (No clinical adenopathy and either pathologically negative or no pathological statement)	NA	U	NONE
10	Clinically enlarged palpable lymph node(s) (adenopathy), and either pathologically negative nodes or no pathological statement	NA	U	RN
20	No clinically enlarged palpable lymph node(s) (adenopathy) but pathologically positive lymph node(s)	NA	U	RN
30	Both clinically enlarged palpable lymph node(s) (adenopathy) and pathologically positive lymph node(s) Lymph nodes, NOS	NA	U	RN
99	Unknown; not stated Regional lymph node(s) cannot be assessed Not documented in patient record	NA	U	U

Kaposi Sarcoma of All Sites

CS Reg Nodes Eval

Code	Description	Staging Basis
9	Not applicable for this site	NA

Kaposi Sarcoma of All Sites

Reg LN Pos

SEE STANDARD TABLE

Kaposi Sarcoma of All Sites

Reg LN Exam

SEE STANDARD TABLE

**Kaposi Sarcoma of All Sites
CS Mets at DX**

Code	Description	TNM	SS77	SS2000
88	Not applicable	NA	U	U

**Kaposi Sarcoma of All Sites
CS Mets Eval**

Code	Description	Staging Basis
9	Not applicable for this site	NA

**Kaposi Sarcoma of All Sites
CS Site-Specific Factor 1 Associated with HIV/AIDS**

* HIV (Human Immunodeficiency Virus) includes types I and II. Older terminology includes HTLV-3 and LAV.

Code	Description
001	Yes/Present
002	No/Not present
999	Unknown if present or not Insufficient information Not documented in patient record

**Kaposi Sarcoma of All Sites
CS Site-Specific Factor 2**

Code	Description
888	Not applicable for this site

**Kaposi Sarcoma of All Sites
CS Site-Specific Factor 3**

Code	Description
888	Not applicable for this site

**Kaposi Sarcoma of All Sites
CS Site-Specific Factor 4**

Code	Description
888	Not applicable for this site

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 5

Code	Description
888	Not applicable for this site

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 6

Code	Description
888	Not applicable for this site

LYMPH NODES

Lymph Nodes C770–C779

Primary Site - Nodal vs Extra-nodal

1. When **multiple lymph node chains** are involved at the time of **diagnosis**, do not simply code the lymph node chain that was biopsied.
 - a. If it is possible to determine where the disease originated, code the primary site to that lymph node chain.
 - b. If multiple lymph node chains are involved and it is not possible to determine the lymph node chain where the disease originated, code the primary site to C778, lymph nodes of multiple regions.
2. If a lymphoma is **extranodal**, code the organ of origin.

Example: Pathology from stomach resection shows lymphoma. No other pathologic or clinical disease identified. Code the primary site as stomach, NOS (C169).

3. If a lymphoma is present both in an **extranodal site and** in that organ's **regional lymph nodes**, code the extralymphatic organ as the primary site. The only exception would be if the lymphoma in the extranodal site were a direct extension from the regional nodes. Lymphomas can spread from the regional lymph nodes into an extranodal site only by direct extension.

Example 1: Lymphoma is present in the spleen and splenic lymph nodes. Code the primary site to spleen (C422).

Example 2: Lymphoma is present in the stomach and the gastric lymph nodes. Code the primary site to stomach, NOS (C169).

4. If the lymphoma is present in **extralymphatic organ(s) and non-regional lymph nodes**, consult the physician to determine a primary site. If a site cannot be determined, code Lymph Node, NOS (C779).
5. If the **primary site is unknown** or not given:
 - a. Code retroperitoneal lymph nodes if described as retroperitoneal mass
 - b. Code inguinal lymph nodes if described as inguinal mass
 - c. Code mediastinal lymph nodes if described as mediastinal mass
 - d. Code mesenteric lymph nodes if described as mesenteric mass
 - e. If the primary site is unknown code Lymph Nodes, NOS (C779)

Exception: Code unknown primary site (C809) only when there is no evidence of lymphoma in lymph nodes and/or the medical record documents that the physician suspects that it is an extranodal lymphoma

Code mycosis fungoides and cutaneous lymphomas to Skin (C44_).

Grade

DO NOT code the **descriptions** “high grade,” “low grade,” or “intermediate grade” in the Grade, Differentiation or Cell Indicator field.

FOR LYMPHOMA ONLY, the terms “high grade,” “low grade,” and “intermediate grade” refer to the Working Formulation of lymphoma diagnoses. The Working Formulation is not a grade or differentiation. DO NOT code the descriptions “Grade 1,” “Grade 2,” or “Grade 3” in the Grade, Differentiation or Cell Indicator field.

FOR LYMPHOMA ONLY, the terms “Grade 1,” “Grade 2,” and “Grade 3” represent lymphoma types, rather than differentiation.

- a The designation of T-cell, B-cell, null cell, or NK cell has **precedence** over any statement of grading or differentiation
- b Code ANY statement of T-cell, B-cell, null cell, or NK cell
- c Code information on cell type from **any source**, whether or not marker studies are documented in the patient record

Example: The history portion of the medical record documents that the patient has a T-cell lymphoma. There are no marker studies in the chart. Code the grade as T-cell.

Additional Terms to be Coded

T-cell (code 5)
T-cell phenotype
T-precursor
Pre-T
Gamma-Delta T

B-Cell (code 6)
B-cell phenotype
B-precursor
Pre-B

Null-Cell; Non-T-non-B (code 7)
Null-cell
Non T-non-B
Common cell

NK (natural killer) cell (code 8)
Nasal NK/T cell lymphoma
Cell type not determined, not stated, not applicable (code 9)
Combined T and B cell

Regional Lymph Nodes Positive and Regional Lymph Nodes Examined

Because lymphomas frequently arise in nodal sites, these two fields are always coded '99' for both nodal and extranodal lymphomas.

Collaborative Staging Codes

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

(ICD-O-3 M-959-972 EXCEPT 9700/3 and 9701/3)

CS Tumor Size	CS Site-Specific Factor 1 - Associated with HIV/AIDS	The following tables are available at the collaborative staging website: Histologies for Which AJCC Staging Is Not Generated AJCC Stage Extension Stage Table
CS Extension	CS Site-Specific Factor 2 - Systemic Symptoms at Diagnosis	
CS TS/Ext-Eval	CS Site-Specific Factor 3 - IPI Score	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Reg Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam		
CS Mets at DX		
CS Mets Eval		

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Tumor Size

Code	Description
888	Not applicable

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Extension

Note 1: For Hodgkin Lymphoma an E lesion is defined as disease that involves extralymphatic site(s).

Extralymphatic means other than lymph nodes and other lymphatic structures. These lymphatic structures include spleen, thymus gland, Waldeyer's ring (tonsils), Peyer's patches (ileum) and lymphoid nodules in the appendix. Any lymphatic structure is to be coded the same as a lymph node region.

Note 2: S equals Spleen involvement.

Note 3: If there is no mention of extranodal involvement but several diagnostic procedures were done, including laparotomy, interpret as no involvement.

Note 4: Involvement of adjacent soft tissue does not alter the classification.

Code	Description	TNM	SS77	SS2000
10	Involvement of a single lymph node region Stage I	*	L	L
11	Localized involvement of a single extralymphatic organ/ site in the absence of any lymph node involvement Multifocal involvement of one extralymphatic organ/site Stage IE	*	L	L
12	Involvement of spleen only Stage IS	*	L	L
20	Involvement of two or more lymph node regions on the SAME side of the diaphragm Stage II	*	RNOS	RNOS
21	Localized involvement of a single extralymphatic organ/site WITH involvement of its regional lymph node(s) or WITH or WITHOUT involvement of other lymph node(s) on the SAME side of the diaphragm Direct extension to adjacent organs or tissues	*	RNOS	RNOS

21, cont'd	Stage IIE			
22	Involvement of spleen PLUS lymph node(s) BELOW the diaphragm Stage IIS	*	RNOS	RNOS
23	Involvement of spleen PLUS involvement of a single extralymphatic organ/site BELOW the diaphragm WITH or WITHOUT involvement of lymph node(s) BELOW the diaphragm Stage IIES	*	RNOS	RNOS
30	Involvement of lymph node regions on BOTH sides of the diaphragm Stage III	*	D	D
31	Involvement of an extralymphatic organ/site PLUS involvement of lymph node(s) on the OPPOSITE side of the diaphragm Stage IIIE	*	D	D
32	Involvement of the spleen PLUS lymph node(s) ABOVE the diaphragm Stage IIIS	*	D	D
33	(31) + (32) OR Involvement of the spleen PLUS a single extralymphatic site ABOVE the diaphragm WITH or WITHOUT involvement of lymph node(s) Involvement of the spleen PLUS involvement of lymph node region(s) ABOVE the diaphragm PLUS involvement of a single extralymphatic organ/site on either side of the diaphragm Stage IIIES	*	D	D
80	Diffuse or disseminated (multifocal) involvement of ONE OR MORE extralymphatic organ(s)/site(s) WITH or WITHOUT associated lymph node involvement Multifocal involvement of MORE THAN ONE extralymphatic organ/site Involvement of isolated extralymphatic organ in absence of involvement of adjacent lymph nodes, but in conjunction with disease in distant sites Metastasis/involvement: Bone marrow Liver Nodular involvement of lung(s) Stage IV	*	D	D
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	*	U	U

* AJCC stage group for this site is derived directly from the extension code, as shown in the Extension Stage Table. For extension codes 10-80, the AJCC Stages Groups I-IV are subdivided into A and B based on presence or absence of symptoms as shown in the Symptom Stage Subgroup Table.

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS TS/Ext-Eval

Note: According to AJCC, "The use of the term pathologic staging is reserved for patients who undergo staging laparotomy with an explicit intent to assess the presence of abdominal disease or to define histologic microscopic disease extent in the abdomen. Staging laparotomy and pathological staging have been essentially abandoned as useful procedures." (6th ed., page 396) Therefore, Collaborative Staging uses a modified evaluation scheme for lymphomas, and it applies to the CS TS/EXT-EVAL field only. The other EVAL fields are coded as "not applicable" for this schema

Code	Description	Staging Basis
0	No staging laparotomy done. No autopsy evidence used.	c
3	Staging laparotomy done.	p
8	Evidence from autopsy only (tumor was unsuspected or undiagnosed prior to autopsy)	a
9	Unknown if staging laparotomy done Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Lymph Nodes

Code	Description	TNM	SS77	SS2000
88	Not applicable	NA	U	U

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Reg Nodes Eval

Code	Description	Staging Basis
9	Not applicable for this site.	NA

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

Reg LN Pos

Code	Description
99	Not applicable for this site

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

Reg LN Exam

Code	Description
99	Not applicable for this site

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Mets at DX

Code	Description	TNM	SS77	SS2000
88	Not applicable	NA	U	U

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Mets Eval

Code	Description	Staging Basis
9	Not applicable for this site.	NA

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 1 Associated with HIV/AIDS

Note: HIV (Human Immunodeficiency Virus) includes types I and II. Older terminology includes HTLV-3 and LAV.

Code	Description
001	Yes/Present
002	No/Not present
999	Unknown if present or not insufficient information Not documented in patient record

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 2 Systemic Symptoms at Diagnosis

Note 1: Each stage should be classified as either A or B according to the absence or presence of defined constitutional symptoms, such as: 1. Fevers: Unexplained fever with temperature above 38 degrees C; 2. Night sweats: Drenching sweats that require change of bedclothes; 3. Weight loss: Unexplained weight loss of more than 10% of the usual body weight in the 6 months prior to diagnosis.

Note 2: Pruritus alone does not qualify for B classification, nor does alcohol intolerance, fatigue, or a short, febrile illness associated with suspected infections.

Code	Description	Modifier
000	No B symptoms (Asymptomatic)	A

010	Any B symptoms: Night sweats Unexplained fever (above 38 degrees C) Unexplained weight loss (generally greater than 10% loss of body weight in the six months before admission) B symptoms, NOS	B
020	Pruritis (if recurrent and unexplained)	B
030	(010) + (020)	B
999	Unknown if symptoms; insufficient information Not documented in patient record	BLANK

The "A" or "B" is appended to the stage I-IV as determined in the data item CS Site-Specific Factor 2, Systemic Symptoms at Diagnosis.

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 3 IPI Score

Note: Record the IPI (International Prognostic Index) as stated in the medical record.

Code	Description	Risk Group
000	0 points	Low
001	1 point	Low
002	2 points	Low intermediate
003	3 points	High intermediate
004	4 points	High
005	5 points	High
999	Unknown Insufficient information Not documented in patient record	

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 4

Code	Description
888	Not applicable for this site

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 5

Code	Description
888	Not applicable for this site

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 6

Code	Description
888	Not applicable for this site

Collaborative Staging Codes Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

(M-9731-9734, 9740-9742, 9750-9758, 9760-9762, 9764-9769, 9800-9801, 9805, 9820, 9823, 9826-9827, 9831-9837, 9840, 9860-9861, 9863, 9866-9867, 9870-9876, 9891, 9895-9897, 9910, 9920, 9930-9931, 9940, 9945-9946, 9948, 9950, 9960-9964, 9970, 9975, 9980, 9982-9987, 9989)

Note: This list includes only preferred terms from ICD-O-3

9731 Plasmacytoma, NOS
9732 Multiple myeloma
9733 Plasma cell leukemia
9734 Plasmacytoma, extramedullary
9740 Mast cell sarcoma
9741 Malignant mastocytosis
9742 Mast cell leukemia
9750 Malignant histiocytosis
9751 Langerhans cell histiocytosis, NOS*
9752 Langerhans cell histiocytosis, unifocal*
9753 Langerhans cell histiocytosis, multifocal*
9754 Langerhans cell histiocytosis disseminated
9755 Histiocytic sarcoma
9756 Langerhans cell sarcoma
9757 Interdigitating dendritic cell sarcoma
9758 Follicular dendritic cell sarcoma
9760 Immunoproliferative disease, NOS
9761 Waldenstrom macroglobulinemia
9762 Heavy chain disease, NOS
9764 Immunoproliferative small intestinal disease
9765 Monoclonal gammopathy of undetermined
significance*
9766 Angiocentric immunoproliferative lesion*
9767 Angioimmunoblastic lymphadenopathy*
9768 T-gamma lymphoproliferative disease*
9769 Immunoglobulin deposition disease*
9800 Leukemia, NOS
9801 Acute leukemia, NOS
9805 Acute biphenotypic leukemia
9820 Lymphoid leukemia, NOS
9823 B-cell chronic lymphocytic leukemia/small
lymphocytic lymphoma
9826 Burkitt cell leukemia
9827 Adult T-cell leukemia/lymphoma (HTLV-1
positive)
9831 T-cell large granular lymphocytic leukemia*
9832 Prolymphocytic leukemia, NOS
9833 Prolymphocytic leukemia, B-cell type
9834 Prolymphocytic leukemia, T-cell type
9835 Precursor cell lymphoblastic leukemia, NOS
9836 Precursor B-cell lymphoblastic leukemia
9837 Precursor T-cell lymphoblastic leukemia
9840 Acute myeloid leukemia, M6 type
9860 Myeloid leukemia, NOS
9861 Acute myeloid leukemia, NOS
9863 Chronic myeloid leukemia
9866 Acute promyelocytic leukemia

*Usually considered of uncertain/borderline behavior

Collaborative Staging Codes
Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative
Neoplasms (cont).

(M-9731-9734, 9740-9742, 9750-9758, 9760-9762, 9764-9769, 9800-9801, 9805, 9820, 9823, 9826-9827, 9831-9837, 9840, 9860-9861, 9863, 9866-9867, 9870-9876, 9891, 9895-9897, 9910, 9920, 9930-9931, 9940, 9945-9946, 9948, 9950, 9960-9964, 9970, 9975, 9980, 9982-9987, 9989)

Note: This list includes only preferred terms from ICD-O-3

9867 Acute myelomonocytic leukemia
9870 Acute basophilic leukemia
9871 Acute myeloid leukemia with abnormal marrow, eosinophils
9872 Acute myeloid leukemia, minimal differentiation
9873 Acute myeloid leukemia without maturation
9874 Acute myeloid leukemia with maturation
9875 Chronic myelogenous leukemia, BCR/ABL positive
9876 Atypical chronic myeloid leukemia BCR/ABL negative
9891 Acute monocytic leukemia
9895 Acute myeloid leukemia with multilineage dysplasia
9896 Acute myeloid leukemia, t(8;21)(q22;q22)
9897 Acute myeloid leukemia, 11q23 abnormalities
9910 Acute megakaryoblastic leukemia
9920 Therapy-related acute myeloid leukemia, NOS
9930 Myeloid sarcoma
9931 Acute panmyelosis with myelofibrosis
9940 Hairy cell leukemia
9945 Chronic myelomonocytic leukemia, NOS
9946 Juvenile myelomonocytic leukemia
9948 Aggressive NK-cell leukemia
9950 Polycythemia (rubra) vera
9960 Chronic myeloproliferative disease, NOS
9961 Myelosclerosis with myeloid metaplasia
9962 Essential thrombocythemia
9963 Chronic neutrophilic leukemia
9964 Hypereosinophilic syndrome
9970 Lymphoproliferative disorder, NOS*
9975 Myeloproliferative disease, NOS*
9980 Refractory anemia, NOS
9982 Refractory anemia with sideroblasts
9983 Refractory anemia with excess blasts
9984 Refractory anemia with excess blasts in transformation
9985 Refractory cytopenia with multilineage dysplasia
9986 Myelodysplastic syndrome with 5q deletion (5q-) syndrome
9987 Therapy-related myelodysplastic syndrome, NOS
9989 Myelodysplastic syndrome, NOS

*Usually considered of uncertain/borderline behavior

Collaborative Staging Codes

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

Note: AJCC does not define TNM staging for this site.

CS Tumor Size	CS Site-Specific Factor 1	The following tables are available at the collaborative staging website: Histologies for Which AJCC Staging Is Not Generated AJCC Stage
CS Extension	CS Site-Specific Factor 2	
CS TS/Ext-Eval	CS Site-Specific Factor 3	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Reg Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam		
CS Mets at DX		
CS Mets Eval		

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Tumor Size

Code	Description
888	Not applicable

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Extension

Code	Description	TNM	SS77	SS2000
10	Localized disease: (single/solitary/unifocal/isolated/mono-ostotic) may be coded for: Plasmacytoma, NOS (M-9731/3) (solitary myeloma) Mast cell sarcoma (M-9740) Malignant histiocytosis (M-9750) Histiocytic sarcoma (M-9755) Langerhans cell sarcoma (M-9756) Dendritic cell sarcoma (M-9757, M-9758) Myeloid sarcoma (M-9930)	NA	L	L
80	Systemic disease (poly-ostotic): All histologies including those in 10	NA	D	D
99	Unknown	NA	D	D

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS TS/Ext-Eval

Code	Description	Staging Basis
9	Not applicable for this site	NA

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Lymph Nodes

Code	Description	TNM	SS77	SS2000
88	Not applicable	NA	U	U

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Reg Nodes Eval

Code	Description	Staging Basis
9	Not applicable for this site	NA

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

Reg LN Pos

Code	Description
99	Not applicable.

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

Reg LN Exam

Code	Description
99	Not applicable.

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Mets at DX

Code	Description	TNM	SS77	SS2000
88	Not applicable	NA	U	U

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Mets Eval

Code	Description	Staging Basis
9	Not applicable for this site	NA

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 1

Code	Description
888	Not applicable for this site

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 2

Code	Description
888	Not applicable for this site

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 3

Code	Description
888	Not applicable for this site

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 4

Code	Description
888	Not applicable for this site

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 5

Code	Description
888	Not applicable for this site

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 6

Code	Description
888	Not applicable for this site

Page intentionally blank

Collaborative Staging Codes

Other and Ill-Defined Sites, Unknown Primary Site

C42.0-C42.4, C76.0-C76.5, C76.7-C76.8, C77.0-C77.5, C77.8-C77.9, C80.9

Note: C42._ and C77._, Other than hematopoietic, reticuloendothelial, immunoproliferative and myeloproliferative neoplasms, Hodgkin and non-Hodgkin lymphomas, and Kaposi sarcoma

C42.0 Blood

C42.1 Bone marrow

C42.2 Spleen

C42.3 Reticuloendothelial system, NOS

C42.4 Hematopoietic system, NOS

C76.0 Head, face or neck, NOS

C76.1 Thorax, NOS

C76.2 Abdomen, NOS

C76.3 Pelvis, NOS

C76.4 Upper limb, NOS

C76.5 Lower limb, NOS

C76.7 Other ill-defined sites

C76.8 Overlapping lesion of ill-defined sites

C77.0 Head, face and neck

C77.1 Intrathoracic

C77.2 Intra-abdominal

C77.3 Axilla or arm

C77.4 Inguinal region or leg

C77.5 Pelvis

C77.8 Lymph nodes of multiple regions

C77.9 Lymph nodes, NOS

C80.9 Unknown primary site

Note: AJCC does not define TNM staging for this site.

CS Tumor Size	CS Site-Specific Factor 1	The following tables are available at the collaborative staging website: Histologies for Which AJCC Staging Is Not Generated AJCC Stage
CS Extension	CS Site-Specific Factor 2	
CS TS/Ext-Eval	CS Site-Specific Factor 3	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Reg Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam		
CS Mets at DX		
CS Mets Eval		

Other and Ill-Defined Sites, Unknown Primary Site

CS Tumor Size

SEE STANDARD TABLE

Other and Ill-Defined Sites, Unknown Primary Site

CS Extension

Code	Description	TNM	SS77	SS2000
88	Not applicable for this site	NA	U	U

**Other and Ill-Defined Sites, Unknown Primary Site
CS TS/Ext-Eval**

Code	Description	Staging Basis
9	Not applicable for this site	NA

**Other and Ill-Defined Sites, Unknown Primary Site
CS Lymph Nodes**

Code	Description	TNM	SS77	SS2000
88	Not applicable	NA	U	U

**Other and Ill-Defined Sites, Unknown Primary Site
CS Reg Nodes Eval**

Code	Description	Staging Basis
9	Not applicable for this site	NA

**Other and Ill-Defined Sites, Unknown Primary Site
Reg LN Pos**

Code	Description
99	Not applicable.

**Other and Ill-Defined Sites, Unknown Primary Site
Reg LN Exam**

Code	Description
99	Not applicable.

**Other and Ill-Defined Sites, Unknown Primary Site
CS Mets at DX**

Code	Description	TNM	SS77	SS2000
88	Not applicable	NA	U	U

**Other and Ill-Defined Sites, Unknown Primary Site
CS Mets Eval**

Code	Description	Staging Basis
9	Not applicable for this site	NA

**Other and Ill-Defined Sites, Unknown Primary Site
CS Site-Specific Factor 1**

Code	Description
888	Not applicable for this site

**Other and Ill-Defined Sites, Unknown Primary Site
CS Site-Specific Factor 2**

Code	Description
888	Not applicable for this site

**Other and Ill-Defined Sites, Unknown Primary Site
CS Site-Specific Factor 3**

Code	Description
888	Not applicable for this site

**Other and Ill-Defined Sites, Unknown Primary Site
CS Site-Specific Factor 4**

Code	Description
888	Not applicable for this site

**Other and Ill-Defined Sites, Unknown Primary Site
CS Site-Specific Factor 5**

Code	Description
888	Not applicable for this site

**Other and Ill-Defined Sites, Unknown Primary Site
CS Site-Specific Factor 6**

Code	Description
888	Not applicable for this site

Page intentionally blank

Collaborative Staging Codes
Standard Tables
ICD-O-3 Site Code, Histology, Behavior

CS Tumor Size CS TS/Ext-Eval CS Reg Nodes Eval CS Mets Eval Reg LN Pos Reg LN Exam CS Mets at DX	The following tables are available at the collaborative staging website: Summary Stage Valid ICD-O-3 Site Codes Valid ICD-O-3 Histology Codes T Allowable Codes N Allowable Codes M Allowable Codes Stage Allowable Codes Summary Stage Allowable Codes
--	---

Standard Tables
CS Tumor Size

Code	Description
000	No mass/tumor found
001-988	001 - 988 millimeters (code exact size in millimeters)
989	989 millimeters or larger
990	Microscopic focus or foci only, no size of focus given
991	Described as less than 1 cm
992	Described as less than 2 cm
993	Described as less than 3 cm
994	Described as less than 4 cm
995	Described as less than 5 cm
999	Unknown; size not stated Not documented in patient record

Standard Tables
CS TS/Ext-Eval

Code	Description	Staging Basis
0	No surgical resection done. Evaluation based on physical examination, imaging examination, or other non-invasive clinical evidence. No autopsy evidence used.	c
1	No surgical resection done. Evaluation based on endoscopic examination, diagnostic biopsy, including fine needle aspiration biopsy, or other invasive techniques including surgical observation without biopsy. No autopsy evidence used. Does not meet criteria for AJCC pathological T staging.	c
2	No surgical resection done, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy).	p

3	Surgical resection performed WITHOUT pre-surgical systemic treatment or radiation OR surgical resection performed, unknown if pre-surgical systemic treatment or radiation performed. Evidence acquired before treatment, supplemented or modified by the additional evidence acquired during and from surgery, particularly from pathologic examination of the resected specimen. Meets criteria for AJCC pathological T staging.	p
5	Surgical resection performed WITH pre-surgical systemic treatment or radiation, BUT tumor size/extension based on clinical evidence.	c
6	Surgical resection performed WITH pre-surgical systemic treatment or radiation; tumor size/extension based on pathologic evidence.	y
8	Evidence from autopsy only (tumor was unsuspected or undiagnosed prior to autopsy).	a
9	Unknown if surgical resection done Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

Standard Tables

CS Reg Nodes Eval

Note: This item reflects the validity of the classification of the item CS Lymph Nodes only according to diagnostic methods employed.

Code	Description	Staging Basis
0	No regional lymph nodes removed for examination. Evidence based on physical examination, imaging examination, or other non-invasive clinical evidence. No autopsy evidence used.	c
1	No regional lymph nodes removed for examination. Evidence based on endoscopic examination, diagnostic biopsy including fine needle aspiration of lymph node(s) or other invasive techniques, including surgical observation without biopsy. No autopsy evidence used.	c
2	No regional lymph nodes removed for examination, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy).	p
3	Regional lymph nodes removed for examination (removal of at least 1 lymph node) WITHOUT pre-surgical systemic treatment or radiation OR lymph nodes removed for examination, unknown if pre-surgical systemic treatment or radiation performed.	p
5	Regional lymph nodes removed for examination WITH pre-surgical systemic treatment or radiation, BUT lymph node evaluation based on clinical evidence.	c
6	Regional lymph nodes removed for examination WITH pre-surgical systemic treatment or radiation, and lymph node evaluation based on pathologic evidence.	y
8	Evidence from autopsy; tumor was unsuspected or undiagnosed prior to autopsy.	a
9	Unknown if lymph nodes removed for examination Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

Standard Tables

Reg LN Pos

Note: Record this field even if there has been preoperative treatment.

Code	Description
00	All nodes examined negative.
01-89	1 - 89 nodes positive (code exact number of nodes positive)
90	90 or more nodes positive
95	Positive aspiration of lymph node(s)
97	Positive nodes - number unspecified
98	No nodes examined
99	Unknown if nodes are positive; not applicable Not documented in patient record

Standard Tables

Reg LN Exam

Code	Description
00	No nodes examined
01-89	1 - 89 nodes examined (code exact number of regional lymph nodes examined)
90	90 or more nodes examined
95	No regional nodes removed, but aspiration of regional nodes performed
96	Regional lymph node removal documented as sampling and number of nodes unknown/not stated
97	Regional lymph node removal documented as dissection and number of nodes unknown/not stated
98	Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection; nodes examined, but number unknown
99	Unknown if nodes were examined; not applicable or negative Not documented in patient record

Standard Tables

CS Mets at DX

Code	Description	TNM	SS77	SS2000
00	No; none	M0	NONE	NONE
10	Distant lymph node(s)	M1	D	D
40	Distant metastasis, NOS Distant metastases except distant lymph node(s) (code 10) Carcinomatosis	M1	D	D
50	(10) + (40)	M1	D	D

50, cont'd	Distant lymph node(s) plus other distant metastases			
99	Unknown if distant metastasis Cannot be assessed Not documented in patient record	MX	U	U

Standard Tables

CS Mets Eval

Note: This item reflects the validity of the classification of the item CS Mets at DX only according to the diagnostic methods employed.

Code	Description	Staging Basis
0	No pathologic examination of metastatic tissue performed. Evaluation based on physical examination, imaging examination, and/or other non-invasive clinical evidence. No autopsy evidence used.	c
1	No pathologic examination of metastatic tissue performed. Evaluation of distant metastasis based on endoscopic examination or other invasive technique, including surgical observation without biopsy. No autopsy evidence used.	c
2	No pathologic examination of metastatic tissue done prior to death, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy).	p
3	Pathologic examination of metastatic tissue performed WITHOUT pre-surgical systemic treatment or radiation OR pathologic examination of metastatic tissue performed, unknown if pre-surgical systemic treatment or radiation performed.	p
5	Pathologic examination of metastatic tissue performed WITH pre-surgical systemic treatment or radiation, BUT metastasis based on clinical evidence.	c
6	Pathologic examination of metastatic tissue performed WITH pre-surgical systemic treatment or radiation, and metastasis based on pathologic evidence.	y
8	Evidence from autopsy, and; tumor was unsuspected or undiagnosed prior to autopsy.	a
9	Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c